Potential Taste and Smell Issues Linked to GLP-1 Medications

A recent study might give you pause if you’re using GLP-1 medications like semaglutide, which is found in drugs such as Ozempic and Wegovy. Researchers from the Hebrew University of Jerusalem looked into the medical records of individuals with type 2 diabetes. They found that those using GLP-1 medications had a significantly higher likelihood of being diagnosed with taste or smell issues compared to those on other diabetes treatments. Although the overall risk seems small, they believe further research is necessary to determine if GLP-1s adversely affect sensory perception for some people.

“This study suggests that GLP-1 receptor agonists may be associated with an increased risk of smell and taste disturbances,” noted Nir Zontag, a co-author of the study.

GLP-1 Medications: The Ups and Downs

While GLP-1 drugs have revolutionized the management of type 2 diabetes and obesity, no medication is completely without risks. As these drugs have gained popularity in recent years, researchers have uncovered various, albeit rare, side effects tied to their use.

Some recent reports have connected taste and smell issues to GLP-1 usage, prompting the current study. The researchers analyzed data from a vast patient database that includes records from over 170 healthcare centers around the globe. They compared outcomes from about 439,000 type 2 diabetes patients using a GLP-1 with a similar-sized group on a different medication, matched for age and other factors.

In both groups, the rate of newly reported taste or smell issues was low, but GLP-1 users were still 48% more likely to develop such problems. Specifically, 0.37% of those on GLP-1 were diagnosed with sensory disruptions, compared to 0.22% of non-users. These issues included conditions like anosmia (loss of smell), parosmia (distorted smell), and parageusia (distorted taste).

The authors emphasized the importance of monitoring these effects closely and raising awareness in public health. Their findings were published in JAMA Otolaryngology–Head & Neck Surgery.

Implications of the Study

This study is retrospective and observational, which means it can’t definitively establish a cause-and-effect relationship between GLP-1 medications and sensory disturbances. Interestingly, some other studies have even indicated that GLP-1 use might enhance taste and smell perception, particularly among patients using it for weight loss rather than diabetes management. So, the relationship between these medications and sensory perception could be quite complex.

“More research is necessary to understand the mechanisms at play, evaluate symptoms more accurately, and assess any impacts on dietary habits and long-term outcomes,” Zontag remarked. It’s noteworthy that both taste buds and the olfactory bulb—the brain region responsible for smell—contain GLP-1 receptors, which could suggest these drugs might influence these areas directly.

Importantly, researchers aren’t suggesting that everyone discontinue their GLP-1 medications. Instead, they emphasize that both doctors and patients should remain vigilant for any sensory changes.

“Even though the absolute risk is low, clinicians and patients should be aware of these potential changes, as they may affect food preferences, nutrition, and overall quality of life,” Zontag said. Timely recognition of such issues could enhance the chances of treatments like olfactory training working effectively to restore a person’s sense of taste and smell.